share_log

Earnings Call Summary | Medtronic(MDT.US) Q4 2024 Earnings Conference

Earnings Call Summary | Medtronic(MDT.US) Q4 2024 Earnings Conference

業績電話會議摘要 | 美敦力(MDT.US)2024 年第四季度業績發佈會
富途資訊 ·  05/24 01:39  · 電話會議

The following is a summary of the Medtronic Plc (MDT) Q4 2024 Earnings Call Transcript:

以下是美敦力集團(MDT)2024年第四季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Medtronic experienced mid-single-digit revenue growth of over 5% for the full fiscal year 2024.

  • The company's earnings per share were $1.46, exceeding consensus.

  • Free cash flow increased by 14% over the previous year to $5.2 billion, indicating financial stability.

  • Medtronic returned $5.5 billion to shareholders through dividends and share repurchases.

  • For FY'25, the company projected organic revenue growth at 4% to 5%.

  • Long-term earnings guidance, excluding currency impact, predicts 9% to 11% growth.

  • 美敦力在2024財年實現了超過5%的中等個位數收入增長。

  • 該公司的每股收益爲1.46美元,超出市場預期。

  • 自由現金流比上年增長14%,達到52億美元,表明財務穩定。

  • 美敦力通過分紅和股票回購向股東返還了55億美元。

  • 該公司預計25財年的有機收入增長爲4%至5%。

  • 不包括貨幣影響在內的長期收益指引預計增長9%至11%。

Business Progress:

業務進展:

  • Medtronic is focusing on restoring their earnings power and is executing cost-out initiatives, pricing maintenance strategies, and maximizing operating overhead efficiencies.

  • Differentiated technology launches in markets like AFib, Structural Heart, robots, and diabetes position the company for durable growth.

  • Substantial growth was observed in the Diabetes business with the rollout of the MiniMed 780G system.

  • The company expanded its Robotics Surgical Technologies sector with the Hugo system.

  • Medtronic expresses confidence in fiscal '25 performance with continued innovation and growth.

  • In terms of business matters, Medtronic is improving pricing and transforming its product mix, including exiting lower-growth business lines.

  • Medtronic shows increased focus on emerging markets, particularly China, and has given emerging market leaders more control over resources for localized healthcare needs.

  • Medtronic's Spine franchise showed improvements and other businesses such as Surgical, AFib, and Hugo are their focus to drive them into growth drivers.

  • 美敦力正專注於恢復盈利能力,正在執行成本削減計劃、爲維護策略定價,並最大限度地提高運營開銷效率。

  • 在AFib、Structural Heart、機器人和糖尿病等市場推出的差異化技術使公司實現了持久增長。

  • 隨着MiniMed 780G系統的推出,糖尿病業務實現了大幅增長。

  • 該公司通過Hugo系統擴大了其機器人外科技術領域。

  • 美敦力對25財年的持續創新和增長表現充滿信心。

  • 在業務方面,美敦力正在改善定價並改變其產品組合,包括退出增長較低的業務線。

  • 美敦力越來越關注新興市場,尤其是中國,並賦予了新興市場領導者對滿足本地醫療需求資源的更多控制權。

  • 美敦力的Spine特許經營權有所改善,Surgical、AFib和Hugo等其他業務是他們的重點,以推動他們進入增長動力。

More details: Medtronic IR

更多詳情: 美敦力 IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論